Skip to main content
Equibles
LGND logo

LGND · Ligand Pharmaceuticals Inc · Webcasts, Transcripts & Audio

Track LGND — free

Use LGND with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LGND.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$322.75 +5.42 (+1.71%) At close · Oct 30 Q3 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$6.43B
Shares
20.00M
Volume · Oct 30 344.37K Avg daily vol (3M) 241.18K

Ligand Pharmaceuticals Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Ligand Pharmaceuticals Inc (LGND), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Capital Markets Day
Investor event
2026-12-08
Ligand Pharmaceuticals Inc (LGND) December 8, 2026 Capital Markets Day
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-30
Ligand Pharmaceuticals Inc (LGND) November 30, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-10
Ligand Pharmaceuticals Inc (LGND) November 10, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-09
Ligand Pharmaceuticals Inc (LGND) November 9, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-10-29
Ligand Pharmaceuticals Inc (LGND) Q3 2026 Earnings Call Transcript
Confident tone Royalty revenue growth Portfolio expansion through Zoma Catalyst-rich pipeline
Revenue
$78.75M
▼ 31.8% YoY
Diluted EPS
$-1.43
▼ 125.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-06
Ligand Pharmaceuticals Inc (LGND) Q2 2026 Earnings Call Transcript
Revenue
$63.69M
▲ 33.7% YoY
Diluted EPS
$2.22
▲ 825% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Ligand Pharmaceuticals Inc (LGND) Q1 2026 Earnings Call Transcript
Confident tone Filspari (sparsentan) franchise Pelvella Qtorin rapamycin (MLM) Investor day and long-term outlook
Revenue
$51.72M
▲ 14.1% YoY
Diluted EPS
$-0.67
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Ligand Pharmaceuticals Inc (LGND) Q4 2025 Earnings Call Transcript
Confident tone FILSPARI FSGS and IgAN market opportunity Royalty portfolio growth and key products Pelvella/SELVA trial and QTORIN rapamycin
Revenue
$59.67M*
▲ 39.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Ligand Pharmaceuticals Inc (LGND) Q3 2025 Earnings Call Transcript
Confident tone ZELSUVMI / Pelthos launch Product launches (Ohtuvayre, FILSPARI, CAPVAXIVE) Development-stage pipeline (Palvella, AT292)
Revenue
$115.46M
▲ 122.8% YoY
Diluted EPS
$5.68
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Ligand Pharmaceuticals Inc (LGND) Q2 2025 Earnings Call Transcript
Confident tone O2vir / Verona / Merck acquisition Pelthos / Zelsuvmi launch and value creation Pipeline catalysts (Filspari, Agenus, Alda, Qarziba)
Revenue
$47.63M
▲ 14.7% YoY
Diluted EPS
$0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Transcript
Confident tone Commercial product launches (Ohtuvayre, Capvaxive, Zelsuvmi) Filspari label expansion and FSGS sNDA NITRICIL platform and special situations
Revenue
$45.33M
▲ 46.3% YoY
Diluted EPS
$-2.21
▼ 146.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Transcript
Confident tone Castle Creek / D-Fi investment Business development pipeline and opportunity set Zelsuvmi / Pelthos launch and partnership search
Revenue
$42.81M*
▲ 52.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Transcript
Confident tone Travere FILSPARI Ohtuvayre and CAPVAXIVE launches Revenue growth and guidance
Revenue
$51.81M
▲ 57.6% YoY
Diluted EPS
$-0.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Transcript
Confident tone Royalty Portfolio Expansion Investment Activity and Capital Deployment Captisol Business Review
Revenue
$41.53M
▲ 57.5% YoY
Diluted EPS
$-2.88
▼ 2315.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Ligand Pharmaceuticals Inc (LGND) Q1 2024 Earnings Call Transcript
Confident tone Partnered pipeline catalysts Royalty aggregation and investment strategy Zelsuvmi and Pelthos Therapeutics
Revenue
$30.98M
▼ 29.6% YoY
Diluted EPS
$4.75
▲ 103.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Ligand Pharmaceuticals Inc (LGND) Q4 2023 Earnings Call Transcript
Confident tone Approved Products and Commercial Catalysts Pipeline PDUFA Approvals Teriparatide and Competitive Risks
Revenue
$28.10M*
▼ 44.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Ligand Pharmaceuticals Inc (LGND) Q3 2023 Earnings Call Transcript
Revenue
$32.87M
▼ 44.5% YoY
Diluted EPS
$-0.59
▼ 3050% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Ligand Pharmaceuticals Inc (LGND) Q2 2023 Earnings Call Transcript
Revenue
$26.37M
▼ 47.4% YoY
Diluted EPS
$0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Ligand Pharmaceuticals Inc (LGND) Q1 2023 Earnings Call Transcript
Revenue
$43.98M
▲ 20.4% YoY
Diluted EPS
$2.33
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Ligand Pharmaceuticals Inc (LGND) Q4 2022 Earnings Call Transcript
Revenue
$50.38M
▼ 10.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Ligand Pharmaceuticals Inc (LGND) Q3 2022 Earnings Call Transcript
Revenue
$59.22M
▼ 0.8% YoY
Diluted EPS
$0.02
▼ 97.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Ligand Pharmaceuticals Inc (LGND) Q2 2022 Earnings Call Transcript
Revenue
$50.13M
▼ 36.4% YoY
Diluted EPS
$-0.05
▼ 102.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Ligand Pharmaceuticals Inc (LGND) Q1 2022 Earnings Call Transcript
Revenue
$36.52M
▼ 21.6% YoY
Diluted EPS
$-0.91
▼ 186.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-17
Ligand Pharmaceuticals Inc (LGND) Q4 2021 Earnings Call Transcript
Revenue
$56.40M
▼ 19.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Ligand Pharmaceuticals Inc (LGND) Q3 2021 Earnings Call Transcript
Revenue
$59.69M
▲ 42.6% YoY
Diluted EPS
$0.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Ligand Pharmaceuticals Inc (LGND) Q2 2021 Earnings Call Transcript
Revenue
$78.85M
▲ 90.4% YoY
Diluted EPS
$1.79
▲ 35.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-03
Ligand Pharmaceuticals Inc (LGND) Q1 2021 Earnings Call Transcript
Revenue
$46.59M
▲ 40.5% YoY
Diluted EPS
$1.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-03
Ligand Pharmaceuticals Inc (LGND) Q4 2020 Earnings Call Transcript
Revenue
$69.99M
▲ 159.2% YoY
Diluted EPS
$0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-30
Ligand Pharmaceuticals Inc (LGND) Q3 2020 Earnings Call Transcript
Revenue
$41.85M
▲ 68.7% YoY
Diluted EPS
$-0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-03
Ligand Pharmaceuticals Inc (LGND) Q2 2020 Earnings Call Transcript
Revenue
$41.42M
▲ 65.8% YoY
Diluted EPS
$1.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Ligand Pharmaceuticals Inc (LGND) Q1 2020 Earnings Call Transcript
Revenue
$33.16M
▼ 23.7% YoY
Diluted EPS
$-1.46
▼ 104.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-06
Ligand Pharmaceuticals Inc (LGND) Q4 2019 Earnings Call
Revenue
$27.00M
▼ 54.7% YoY
Diluted EPS
$-0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–32 of 32 webcasts
Key facts CIK 886163 CUSIP 53220K504 13F (30d) 134 filings 125 filers Visit website Investor relations